Early Oxygen Requirement in Patients with Mild-to-Moderate COVID-19 Who Received Regdanvimab after Delta-Variant Outbreak
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Regdanvimab is a monoclonal antibody targeted against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and a treatment option for patients with mild-to moderate coronavirus disease 2019 (COVID-19). However, there has been limited information on the clinical effectiveness of regdanvimab in the Delta variant of SARS-CoV-2. Therefore, we aimed to investigate the effectiveness of regdanvimab after the Delta variant was dominant using chronological analysis of regdanvimab use in a real-world setting. Materials and methods: The electrical medical records of patients infected with mild-to-moderate COVID-19 who received regdanvimab within 7 days of symptom onset were reviewed before (February - June 2021) and after (August - November 2021) the Delta variant became predominant in Korea. Clinical outcomes were assessed by the need for oxygen supplementation, time from symptom onset to oxygen requirement, in-hospital mortality, and length of hospitalization. To match the difference between the basic characteristics of the two groups, the clinical outcomes were compared again after 1 : 1 propensity score matching. Results: Patients treated with regdanvimab in the Delta-predominant group were more likely to require oxygen supplementation (17.5% vs. 6.0%, P = 0.019) and had shorter times from symptom onset to supplemental oxygen use (mean ± standard deviation [SD]: 5.8 ± 2.8 vs. 10.0 ± 3.7, P = 0.007) than those in the control group. After propensity score matching, the percentage of patient requiring oxygen supplementation was higher (15.2% vs. 6.1%, P = 0.156), while the time from symptom onset to oxygen supplementation was significantly shorter in the Delta-predominant group (mean ± SD: 4.9 ± 2.1 vs. 10.0 ± 3.7, P = 0.007) than that in the control group. Conclusion: Considering that high proportion of vaccinated patients in the Delta-predominant group, this finding suggests the uncertainty whether the effect of regdanvimab is maintained even during the Delta-predominant period. It is hence necessary to continuously monitor the effectiveness of regdanvimab as new SARS-CoV-2 variants emerge.
Abstract
Background: Regdanvimab is a monoclonal antibody targeted against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and a treatment option for patients with mild-to moderate coronavirus disease 2019 (COVID-19). However, there has been limited information on the clinical effectiveness of regdanvimab in the Delta variant of SARS-CoV-2. Therefore, we aimed to investigate the effectiveness of regdanvimab after the Delta variant was dominant using chronological analysis of regdanvimab use in a real-world setting. Materials and methods: The electrical medical records of patients infected with mild-to-moderate COVID-19 who received regdanvimab within 7 days of symptom onset were reviewed before (February - June 2021) and after (August - November 2021) the Delta variant became predominant in Korea. Clinical outcomes were assessed by the need for oxygen supplementation, time from symptom onset to oxygen requirement, in-hospital mortality, and length of hospitalization. To match the difference between the basic characteristics of the two groups, the clinical outcomes were compared again after 1 : 1 propensity score matching. Results: Patients treated with regdanvimab in the Delta-predominant group were more likely to require oxygen supplementation (17.5% vs. 6.0%, P = 0.019) and had shorter times from symptom onset to supplemental oxygen use (mean ± standard deviation [SD]: 5.8 ± 2.8 vs. 10.0 ± 3.7, P = 0.007) than those in the control group. After propensity score matching, the percentage of patient requiring oxygen supplementation was higher (15.2% vs. 6.1%, P = 0.156), while the time from symptom onset to oxygen supplementation was significantly shorter in the Delta-predominant group (mean ± SD: 4.9 ± 2.1 vs. 10.0 ± 3.7, P = 0.007) than that in the control group. Conclusion: Considering that high proportion of vaccinated patients in the Delta-predominant group, this finding suggests the uncertainty whether the effect of regdanvimab is maintained even during the Delta-predominant period. It is hence necessary to continuously monitor the effectiveness of regdanvimab as new SARS-CoV-2 variants emerge.
참고문헌 (18)
- Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019", N Engl J Med, 382, pp.727~733 (2020)
- "WHO coronavirus (COVID-19) dashboard"[URL]
- Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
- Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019pneumonia in Wuhan, China", JAMA Intern Med, 180, pp.934~943 (2020)
- "Anti-SARS-CoV-2 monoclonal antibodies"[URL]
- Kim JY, "Safety, virologic efficacy, and pharmacokinetics of CT-P59, a neutralizing monoclonal antibody against SARS-CoV-2 spike receptor-binding protein : two randomized, placebo-controlled, phase I studies in healthy individuals and patients with mild SARS-CoV-2 infection", Clin Ther, 43, pp.1706~1727 (2021)
- Streinu-Cercel A, "Efficacy and safety of regdanvimab (CT-P59): a phase 2", 3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate coronavirus disease 2019, 2019, pp.9, ofac053~
- Choi Seong Jin, "Effectiveness of Regdanvimab at Preventing the Need for Oxygen Therapy in Patients with Mild-to-Moderate COVID-19: A Retrospective Cohort Study", Infection and Chemotherapy, 54(1), pp.91~101 (2022), 대한감염학회[DOI]
- Korea Disease Control and Prevention Agency, "Global trends and characteristics of the SARS-CoV-2 Delta variant", Public Health Wkly Rep, 14, pp.2363~2365 (2021)
- Korea Disease Control, "July 2021 status and characteristics of the COVID-19variant virus outbreak in the Republic of Korea", Public Health Wkly Rep, 14, pp.3388~3396 (2021)
- Lee JY, "Effectiveness of regdanvimab treatment in high-risk COVID-19 patients to prevent progression to severe disease", Front Immunol, 12, pp.772320~ (2021)
- Ryu DK, "The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2", Biochem Biophys Res Commun, 578, pp.91~96 (2021)
- Planas D, "Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization", Nature, 596, pp.276~280 (2021)
- Twohig KA, "Hospital admission and emergency care attendance risk for SARS-CoV-2delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study", Lancet Infect Dis, 22, pp.35~42 (2022)
- Sheikh A, "SARS-CoV-2 Delta VOC in Scotland : demographics, risk of hospital admission, and vaccine effectiveness", Lancet, 397, pp.2461~2462 (2021)
- O’Horo JC, "Effectiveness of monoclonal antibodies in preventing severe COVID-19 with emergence of the delta variant", Mayo Clin Proc, 97, pp.327~332 (2022)
- Chen J, "Omicron(B. 1. 1. 529) : Infectivity, vaccine breakthrough, and antibody resistance", J Chem Inf Model, 62, pp.412~422 (2022)
- Dejnirattisai W, "Reduced neutralisation of SARS-CoV-2 omicron B. 1. 1. 529 variant by post-immunisation serum", Lancet, 399, pp.234~236 (2022)